CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach ...

A dark-money group has launched a multi-state bus tour to bring awareness to what they characterize as bad behavior by pharma ...

CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN ...

Novo Nordisk acquired monlunabant in a $1bn deal last year, but the Phase IIa trial raises questions over the efficacy and ...

Sen. Mike Braun has a unique opportunity to hold Novo Nordisk accountable for discontinuing insulin drug Levemir.

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...